Flash Finance

Lupin LimitedLUPINCorporate

Healthcare Drug Manufacturers - Specialty & Generic Latest results: Mar 2026 14 quarters of data
Consolidated Standalone
₹1,961.60
MCap ₹89,697 Cr · P/E 16.7
Lupin Limited — Stock analysis & AI research Lupin Limited — Multibagger AI analysis Lupin Limited — Seasonality — best & worst months Lupin Limited — Technical indicators & charts Lupin Limited — Technical setup — score, trend, support & resistance Lupin Limited — Double Top pattern broken down ↓ Lupin Limited — Live exchange announcements
📋 High ROE Stocks📋 High ROCE Stocks📋 High Operating Margin Stocks📋 High Interest Coverage Stocks📋 Stocks Cheaper Than Their Industry📋 High Profit Growth Stocks 📈 MACD Bullish Crossover📈 Lowest Technical Score📈 Multi-Timeframe Bearish Stocks📈 Stocks Near 52-Week Low 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹7,475 Cr
Sales · Mar 2026
+31.9% YoY
₹2,486 Cr
Operating Profit · Mar 2026
+88.2% YoY
33.3%
OPM % · Mar 2026
+42.9% YoY
₹1,469 Cr
Net Profit · Mar 2026
+87.8% YoY
₹31.94
EPS · Mar 2026
+88.7% YoY

📝 Lupin Limited — results explained

Quarter ended March 2026 (Q4 FY26)

Lupin Limited reported revenue of ₹7,475 crore for the quarter ended March 2026 (Q4 FY26), up 31.9% from ₹5,667 crore in the same quarter last year, and up 4.3% sequentially over the December 2025 quarter.

Net profit rose 87.8% year-on-year to ₹1,469 crore, from ₹782 crore. Earnings per share (EPS) came in at ₹31.94.

Operating profit stood at ₹2,486 crore — an operating margin (OPM) of 33.3%, compared with 23.3% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Lupin Limited posted revenue of ₹27,958 crore, a growth of 23.1% over FY25, with a net profit of ₹5,356 crore (up 62.0% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹27,958 crore with a net profit of ₹5,356 crore.

Valuation snapshot

At the current price of ₹1,961.60, LUPIN has a market capitalisation of ₹89,697 crore and a trailing P/E of about 16.7.

Within the Drug Manufacturers - Specialty & Generic industry, it is the 9th-largest of the 31 companies we track by market value.

Shareholding pattern

As of Jun 2026, promoters held 46.85%, foreign institutional investors (FIIs) 22.42%, domestic institutional investors (DIIs) 24.65%, public shareholders 6.08% of Lupin Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹89,697 Cr
Current Price ?
₹1,961.6
P/E ?
16.75below ind
Industry P/E ?
35.00
P/B ?
4.00
P/S ?
3.21
P/FCF ?
16.23
Enterprise Value ?
₹96,313 Cr
EV/EBITDA ?
10.92
PEG ?
0.12
Earnings Yield ?
7.7%
Dividend Yield ?
0.62%
Profitability & Returns
Sales (TTM) ?
₹27,958 Cr
OPM ?
31.5%
Profit after tax (TTM) ?
₹5,356 Cr
EPS (TTM) ?
₹117.13
ROCE ?
30.0%
ROE ?
23.9%
ROA ?
14.0%
Growth
Sales — latest qtr ?
₹7,475 Cr
PAT — latest qtr ?
₹1,469 Cr
YoY qtr sales growth ?
31.9%
YoY qtr profit growth ?
87.8%
Sales growth (3y) ?
19%
Sales growth (5y) ?
13%
Profit growth (3y) ?
141%
Profit growth (5y) ?
37%
Financial Health
Debt ?
₹6,616 Cr
Debt to Equity ?
0.29
Interest Coverage ?
17.1
Current Ratio ?
N/A
Ownership
Promoter holding ?
46.85%
Change in promoter holding ?
-0.05%
Pledged percentage ?
N/A
Market
Return 3 months ?
-19.7%
Return 6 months ?
-15.7%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Mar bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026 YoY % QoQ %
Sales 2,8614,4304,8145,0395,1974,9615,6005,6735,7685,6676,2687,0487,1687,475 +31.9% +4.3%
Operating Profit 5335788569181,0389971,2411,3401,3561,3211,7272,3412,2622,486 +88.2% +9.9%
Other Income 1837234029296842545779901159 -84.2% -92.2%
Interest 8493868174716871678992108115120 +34.7% +4.4%
Depreciation 220264235248257457248257271393299317313447 +13.7% +42.8%
Profit Before Tax 672585596307364989931,0551,0718961,4162,0071,5221,928 +115.2% +26.7%
Net Profit 402424534906193688068598597821,2211,4851,1811,469 +87.8% +24.4%
EPS 3.375.199.9410.7813.477.8917.5818.7018.7416.9326.7032.3625.7431.94 +88.7% +24.1%
OPM % 18.6% 13.0% 17.8% 18.2% 20.0% 20.1% 22.2% 23.6% 23.5% 23.3% 27.6% 33.2% 31.6% 33.3% +42.9% +5.4%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹22,708 Cr ₹27,958 Cr ₹27,958 Cr +23.1%
Operating Profit ₹5,259 Cr ₹8,816 Cr ₹8,816 Cr +67.7%
OPM % 23.16% 31.53% 31.53% +36.1%
NPM % 14.56% 19.16% 19.16% +31.6%
Other Income ₹221 Cr ₹293 Cr ₹293 Cr +32.3%
Depreciation ₹1,169 Cr ₹1,376 Cr ₹1,376 Cr +17.7%
Interest ₹295 Cr ₹434 Cr ₹434 Cr +47.2%
EBIT ₹4,089 Cr ₹7,441 Cr ₹7,441 Cr +81.9%
PBT ₹4,015 Cr ₹6,873 Cr ₹6,873 Cr +71.2%
Tax ₹309 Cr ₹1,058 Cr ₹1,058 Cr +242.5%
Net Profit ₹3,307 Cr ₹5,356 Cr ₹5,356 Cr +62.0%
EPS ₹71.95 ₹116.74 ₹116.74 +62.3%
Material Cost ₹3,463 Cr ₹5,549 Cr ₹5,549 Cr +60.2%
Employee Cost ₹2,009 Cr ₹3,332 Cr ₹3,332 Cr +65.9%
Extraordinary Items — ₹-427 Cr ₹-427 Cr —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 91919191 +0.0%
Reserves 12,37414,19917,11222,357 +30.7%
Borrowings 4,5422,9225,4486,616 +21.4%
Other Liabilities 5,7946,5396,3279,300 +47.0%
Total Liabilities 22,80023,75128,97838,365 +32.4%
Fixed Assets 8,3558,8789,71911,315 +16.4%
CWIP 1,238773517695 +34.4%
Investments 5171,0751,1463,670 +220.2%
Other Assets 12,69013,02617,59622,685 +28.9%
Total Assets 22,80023,75128,97838,365 +32.4%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 1,8973,6483,0007,334 +144.5%
Cash from Investing Activity -1,287-1,712-4,172-3,865 +7.4%
Cash from Financing Activity -337-2,1841,732-846 -148.8%
Net Cash Flow 273-2485602,624 +368.6%
Free Cash Flow 4362,7321,3475,527 +310.3%
CFO/OP 124%105%74%98% +32.4%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 98868886 -2.3%
Inventory Days 242272292303 +3.8%
Days Payable 136163158208 +31.6%
Cash Conversion Cycle 204195223181 -18.8%
Working Capital Days 32535875 +29.3%
ROCE % 6%16%21%30% +42.9%

👥 Shareholding (latest 5 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 % Chg
Promoters 46.90%46.89%46.89%46.85%46.85% +0.0%
FIIs 21.25%20.50%21.50%21.70%22.42% +3.3%
DIIs 25.55%26.56%25.58%25.32%24.65% -2.6%
Government 0.00%0.00%0.00%0.00%— —
Public 6.28%6.06%6.04%6.13%6.08% -0.8%
No. of Shareholders 2,86,6042,80,2562,88,9312,90,4113,00,283 +3.4%

⚖️ Peer comparison

Industry: Drug Manufacturers - Specialty & Generic · top 25 of 31 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SUNPHARMA Sun Pharmaceutical ₹1,840.00 441,478 36.5 59,911 12,104 29.8% 20.2% 11.2% 5.1% 10.5% 27.0%
2 DIVISLAB Divi's Laboratories ₹9,235.00 245,160 83.8 11,230 2,925 35.3% 26.0% 12.8% 16.7% 27.8% 65.5%
3 TORNTPHARM Torrent Pharmaceuticals ₹4,931.00 187,559 87.1 15,723 2,156 33.0% 13.7% 21.4% 11.9% 54.8% 3.3%
4 ZYDUSLIFE Zydus Lifesciences ₹1,162.20 115,930 23.2 27,148 5,070 31.2% 18.7% 16.8% 12.0% 16.2% 14.5%
5 CIPLA Cipla ₹1,366.00 110,353 32.7 28,324 3,356 18.7% 11.8% 2.2% -26.7% 2.3% -39.2%
6 LAURUSLABS Laurus Labs ₹1,969.00 106,387 97.2 7,270 1,090 28.0% 15.0% 22.7% 147.9% 29.1% 123.9%
7 DRREDDY Dr. Reddy's ₹1,165.50 97,085 29.3 28,704 3,273 15.3% 11.4% -10.4% -25.8% -5.6% -69.2%
8 AUROPHARMA Aurobindo Pharma ₹1,679.80 96,652 26.2 34,935 3,711 20.3% 10.6% 6.1% 0.6% 16.3% 25.2%
9 LUPIN Lupin ₹2,095.00 95,797 17.9 27,958 5,356 31.5% 19.2% 23.1% 62.0% 31.9% 87.8%
10 MANKIND Mankind Pharma ₹2,280.00 94,174 46.1 14,738 2,067 26.0% 14.0% 16.3% -3.7% 12.9% 29.1%
11 GLENMARK Glenmark Pharmaceuticals ₹2,419.20 68,276 38.0 17,737 1,797 27.0% 10.1% -61.2% -67.4% 23.1% 927.9%
12 ALKEM Alkem Laboratories ₹5,243.50 62,694 29.1 15,081 2,187 20.1% 14.5% 13.5% 7.6% 10.9% -21.6%
13 ABBOTINDIA Abbott India ₹25,860.00 54,951 34.0 7,005 1,615 28.1% 23.1% 8.1% 9.7% 4.4% 17.2%
14 IPCALAB Ipca Laboratories ₹1,964.20 49,833 38.0 10,125 1,379 22.0% 13.6% 7.9% 55.0% 20.8% 82.2%
15 GLAND Gland Pharma ₹2,935.90 48,433 47.1 6,431 1,028 25.3% 16.0% -64.7% -48.4% 22.3% 96.7%
16 AJANTPHARM Ajanta Pharma ₹3,398.90 42,472 37.4 5,777 1,135 25.4% 19.7% 17.3% 14.8% 24.8% 30.9%
17 JBCHEPHARM J. B. ₹2,416.10 38,793 53.4 4,148 709 26.7% 17.1% 5.9% 7.5% -4.8% -30.7%
18 EMCURE EMCURE PHARMACEUTICALS ₹1,975.10 37,470 37.0 9,684 1,019 20.4% 10.5% 16.6% 33.1% 22.8% 36.0%
19 WOCKPHARMA Wockhardt ₹2,021.50 32,848 92.5 3,133 353 19.9% 11.3% -2.3% 342.1% 25.9% 199.1%
20 NEULANDLAB Neuland Laboratories ₹23,455.00 30,093 82.7 2,023 365 28.4% 18.0% 37.0% 40.2% 136.3% 666.0%
21 PPLPHARMA Piramal Pharma ₹211.50 28,024 113.5 9,206 247 11.0% 2.7% -3.1% -37.9% 17.4% -161.3%
22 GRANULES Granules India ₹885.60 21,945 32.8 5,633 663 22.7% 11.8% 19.7% 18.8% 22.0% 59.3%
23 CAPLIPOINT Caplin Point ₹2,752.60 20,923 31.4 2,287 678 34.8% 29.7% 12.9% 20.2% 19.6% 18.8%
24 ERIS Eris Lifesciences ₹1,358.00 18,820 29.0 3,230 666 35.2% 20.6% 8.2% 72.6% 13.0% 14.6%
25 ASTRAZEN AstraZeneca Pharma ₹6,755.00 16,888 99.6 2,432 170 9.4% 7.0% 32.7% 62.1% 29.7% -32.1%
❓ Frequently asked questions
What was Lupin Limited's revenue in Q4 FY26?
Lupin Limited reported revenue of ₹7,475 crore for the quarter ended March 2026 (Q4 FY26), up 31.9% from ₹5,667 crore in the same quarter last year, and up 4.3% sequentially over the December 2025 quarter.
What was Lupin Limited's net profit in Q4 FY26?
Net profit rose 87.8% year-on-year to ₹1,469 crore, from ₹782 crore. Earnings per share (EPS) came in at ₹31.94.
What is LUPIN's market capitalisation and P/E ratio?
At the current price of ₹1,961.60, LUPIN has a market capitalisation of ₹89,697 crore and a trailing P/E of about 16.7.
Who owns Lupin Limited? (shareholding pattern)
As of Jun 2026, promoters held 46.85%, foreign institutional investors (FIIs) 22.42%, domestic institutional investors (DIIs) 24.65%, public shareholders 6.08% of Lupin Limited.
TTM ends 2026-03-31. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI